Zacks Investment Research upgraded shares of Urogen Pharma (NASDAQ:URGN) from a hold rating to a buy rating in a research report sent to investors on Wednesday morning. The brokerage currently has $20.00 price objective on the stock.

According to Zacks, “UroGen Pharma Ltd. is a clinical stage biopharmaceutical company. It focused on developing urological pathologies with a focus on uro-oncology. The company’s product candidates include MitoGel and VesiGel which are in clinical trial stage. Its platform technologies include: RTGel and Immunotherapy. UroGen Pharma Ltd. is based in Ra’anana, Israel. “

A number of other brokerages have also recently weighed in on URGN. Raymond James Financial, Inc. began coverage on Urogen Pharma in a research report on Tuesday, May 30th. They issued an outperform rating and a $25.00 price target for the company. Oppenheimer Holdings, Inc. began coverage on Urogen Pharma in a research report on Tuesday, May 30th. They issued an outperform rating and a $32.00 price target for the company. Cowen and Company began coverage on Urogen Pharma in a research report on Tuesday, May 30th. They issued an outperform rating for the company. Finally, Jefferies Group LLC began coverage on Urogen Pharma in a research report on Tuesday, May 30th. They issued a buy rating and a $27.00 price target for the company. Five investment analysts have rated the stock with a buy rating, The stock currently has an average rating of Buy and a consensus price target of $26.00.

Urogen Pharma (NASDAQ:URGN) traded up 5.02% during midday trading on Wednesday, hitting $18.63. 93,101 shares of the stock were exchanged. Urogen Pharma has a one year low of $13.01 and a one year high of $20.02. The stock’s market cap is $223.06 million. The firm has a 50-day moving average price of $17.57 and a 200-day moving average price of $17.49.

ILLEGAL ACTIVITY WARNING: This news story was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another website, it was stolen and reposted in violation of United States & international trademark & copyright law. The original version of this news story can be accessed at https://www.thecerbatgem.com/2017/08/03/urogen-pharma-nasdaqurgn-upgraded-to-buy-at-zacks-investment-research.html.

A number of hedge funds have recently bought and sold shares of the company. Alps Advisors Inc. bought a new stake in Urogen Pharma during the second quarter worth approximately $195,000. LLBH Private Wealth Management LLC bought a new stake in Urogen Pharma during the second quarter worth approximately $695,000. Spark Investment Management LLC bought a new stake in Urogen Pharma during the second quarter worth approximately $856,000. Finally, Menora Mivtachim Holdings LTD. bought a new stake in Urogen Pharma during the second quarter worth approximately $2,331,000. Hedge funds and other institutional investors own 0.23% of the company’s stock.

Urogen Pharma Company Profile

Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract.

Get a free copy of the Zacks research report on Urogen Pharma (URGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related stocks with our FREE daily email newsletter.